'Tentative' FDA nod on Teva drug

Teva is currently in patent litigation over the product after a suit was brought against the company in May 2005. A trial is scheduled to begin in 2007.

By AVI KRAWITZ
February 14, 2006 07:17
teva logo 88

teva logo 88. (photo credit: )

Teva Pharmaceutical Industries Ltd. said Monday it received tentative approval from the US Food and Drug Administration for its abbreviated new drug application (ANDA) for Adenosine Injection, 3 mg/ml in 20 ml and 30 ml single dose vials. On final approval, the injection will be the AP-rated generic equivalent of Astellas Adenoscan Injection, a product used as an supplement to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The brand product has annual sales of approximately $163 million. Teva is currently in patent litigation over the product after a suit was brought against the company in May 2005. A trial is scheduled to begin in 2007.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS